The purpose of this study is to find out whether Revaree Plus is effective at improving vaginal health for people who are having symptoms of vaginal dryness during breast cancer treatment.

Inclusion Criteria:

• ≥18 years of age at the time of signing informed consent.
• Stage 0-3 hormone-receptor positive breast cancer confirmed at MSKCC
• Able to complete study questionnaires in English or Spanish
• Breast cancer patients must have completed primary therapy (surgery, and/or chemotherapy, and/or radiation therapy) or currently on maintenance therapy
• Currently on an aromatase inhibitor or tamoxifen or Selective Estrogen Receptor Modulators (SERM)
• Currently have no clinical evidence of disease
• Reporting being bothered by vaginal symptoms of estrogen deprivation (i.e., vaginal dryness, dyspareunia, or discomfort [pain with intercourse or examination])
• A total score of 4 or greater in VAS
• Without history of other cancers (excluding non-melanoma skin cancer)
• Must sign an informed consent indicating that the participant understands the purpose of, and procedures required for the study and is willing to participate in the study

Exclusion Criteria:

• Inability to provide informed consent
• Vaginal bleeding of unknown etiology within 12 months of study entry
• Currently taking hormone replacement therapy [local or systemic] (Patients must discontinue for 4 weeks in order to be eligible prior to study enrollment)
• Existing use of external estrogens or nonhormonal moisturizers (Patients must discontinue for 4 weeks in order to be eligible prior to study enrollment)
• No known allergies to any ingredients in 10mg HLA suppository

Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.